|Numero di pubblicazione||WO1997009436 A1|
|Tipo di pubblicazione||Richiesta|
|Data di pubblicazione||13 mar 1997|
|Data di registrazione||5 set 1996|
|Data di priorità||5 set 1995|
|Pubblicato anche come||CA2231045A1, EP0850309A1|
|Numero di pubblicazione||PCT/1996/555, PCT/AU/1996/000555, PCT/AU/1996/00555, PCT/AU/96/000555, PCT/AU/96/00555, PCT/AU1996/000555, PCT/AU1996/00555, PCT/AU1996000555, PCT/AU199600555, PCT/AU96/000555, PCT/AU96/00555, PCT/AU96000555, PCT/AU9600555, WO 1997/009436 A1, WO 1997009436 A1, WO 1997009436A1, WO 9709436 A1, WO 9709436A1, WO-A1-1997009436, WO-A1-9709436, WO1997/009436A1, WO1997009436 A1, WO1997009436A1, WO9709436 A1, WO9709436A1|
|Inventori||Tony Vancov, David Zahra, Nicholas John Hawkins, Robyn Lynne Ward|
|Candidato||Crc For Biopharmaceutical Rese, Tony Vancov, David Zahra, Nicholas John Hawkins, Robyn Lynne Ward|
|Esporta citazione||BiBTeX, EndNote, RefMan|
|Citazioni diverse da brevetti (4), Con riferimenti in (41), Classificazioni (16), Eventi legali (9)|
|Link esterni: Patentscope, Espacenet|
METHOD FOR PRODUCING PHAGE DISPLAY VECTORS
The present invention relates to phage display vectors and to methods for producing recombinant phage display vectors. Functional antigen-binding domains of antibodies (heavy and light chain variable domains) can be displayed on the surface of filamentous bacteriophage. International patent application WO 93/19172 describes methods, recombinant host cells and kits for production of antibodies displayed on the surface of phage. To produce a library of great diversity, recombination occurs between two vectors comprising nucleic acid encoding immunoglobulin light and heavy chains respectively producing a recombinant vector encoding the two polypeptide chains. Antibodies displaying the desired antigen binding specificity can be selected from the large number of clones produced by a process called panning. The size of antibody libraries generated using most phage display systems is limited by the low transformation efficiency of Escherichia coli. As the size of the mammalian antibody repertoire is estimated to be in the order of IO6 to IO8, methods for the generation of larger libraries are required. A number of groups have investigated the possibility of increasing the size of antibody libraries by combinatorial infection. In principle, heavy and light chains within the initial library or from the original single chain libraries have been systematically shuffled to obtain libraries of exceptionally larger numbers. Two different mechanisms of site-specific recombination have been used to achieve the association of the two libraries: l. The lox-Cre system of bacteriophage Pl (Waterhouse et al., 1993;
Griffiths et al., 1994; WO 93/19172)
In essence, E.coli is transformed with a repertoire of heavy chain antibody genes (encoded on a phagemid). When Cre recombinase is provided in vivo by infecting the E.coli with Pl, the heavy chains residing on the vector and phagemid are exchanged via the lox-P sites. Chain exchange is, however, reversible. Other disadvantages of using this system include a dependency on infection with a Cre-encoding phage and lack of selection for recombination. 2. The att recombination system of bacteriophage lambda (Geoffroy et al., 1994) This process makes use of lambda phage att recombination sites and the Int recombinase to irreversibly create a chimera between plasmid and phagemid vectors carrying respectively, variable light and variable heavy sequences. E.coli is transformed with a repertoire of light chain antibody sequences (encoded on a phagemid). Selection of the recombinant phagemid is possible by the assembly of a chloramphenicol resistance marker upon the correct recombinational event. These features represent certain advantages over the lox-Cre system, however, contrary to the authors' findings, vectors possessing two functional E.coli origins of replication are inherently unstable. The fact the att recombination system results in the creation of a potentially highly unstable recombinant, detracts from using it to generate large antibody libraries.
A major problem of the methods used to date is that the recombination process is reversible, therefore stable recombinants are not produced. Furthermore, the methods are dependent on infection with a Cre- expressing bacteriophage and the recombinant phagemid only contains one E.coli replicative origin. Furthermore, the methods used to date do not allow the easy selection of recombinants.
Accordingly, in a first aspect the present invention consists in a method for producing a phage display vector, which method includes causing or allowing recombination between
(i) a first vector which includes a sequence encoding a first polypeptide chain of a specific binding pair member; and
(ii) a second phage vector which includes a sequence encoding Cre recombinase operatively linked to a control sequence which allows expression of the cre recombinase and a sequence encoding a second polypeptide chain of a specific binding pair member; wherein either the first or second polypeptide chain is fused to a component of a replicable genetic display package which thereby displays the fused polypeptide at the surface of replicable genetic display packages; and wherein the recombination event gives rise to a recombinant phage vector which includes sequences encoding both the first and second polypeptide chains and in which expression of the Cre recombinase is substantially inhibited. By "operatively linked" we mean that a nucleic acid sequence is placed into a functional relationship with another nucleic acid sequence. For example, a promoter or enhancer is operatively linked to a coding sequence if it affects the transcription of the sequence. In a preferred embodiment of the first aspect of the invention, the second phage vector includes a nucleic acid sequence encoding a promoter sequence, a first recombination site downstream and adjacent to the promoter sequence and an open reading frame for cre-recombinase positioned downstream and adjacent to the recombination site, such that the promoter allows expression of the Cre recombinase sequence; and wherein recombination takes place at the first recombination site such that the open reading frame for Cre recombinase is separated from the promoter sequence. In a further preferred embodiment the promoter sequence is derived from a promoter for a gene encoding a selectable marker. Preferably, the selectable marker is a gene encoding resistance to an antimicrobial agent.
Preferably, the antimicrobial agent is chloramphenicol. In a further embodiment, the promoter is an inducible promoter. The inducible promoter may provide increased control over initiation of the recombination event. In a further preferred embodiment the second phage vector also includes a terminator sequence positioned downstream of the Cre recombinase open reading frame in order to prevent undesired transcription of genes downstream of the Cre recombinase gene. The terminator may be the rrnbTlT2 terminator sequence.
In a further preferred embodiment of the invention, the first vector includes a first recombination site upstream and adjacent to a sequence encoding an open reading frame of a selectable marker, wherein recombination results in the positioning of the sequence encoding the open reading frame of a selectable marker on the recombinant phage vector adjacent to and downstream of the promoter sequence such that the promoter sequence allows expression of the selectable marker. The selectable marker may, for example, be a gene encoding resistance to an antimicrobial gene, or a gene that reacts with a chromogenic compound such as the lacZ gene or the X-gal gene. In a preferred embodiment the selectable marker is a gene encoding resistance to an antimicrobial agent. Preferably, the antimicrobial agent is chloramphenicol. In a further preferred embodiment the first and second vectors each include a first recombination site and a second recombination site different from the first, site-specific recombination taking place between first recombination sites on the first and second vectors and between second recombination sites on the first and second vectors, but not between the first recombination site and the second recombination site on the same vector. Preferably, the first recombination site is the loxP sequence. The second recombination site is preferably a mutant loxP sequence, more preferably the iαxPδll sequence. In a preferred form of the invention the first vector is a plasmid and recombination takes place in a bacterial host.
The recombination event may give rise to a second recombinant vector which contains a sequence comprising the Cre recombinase open reading frame. In order to prevent expression of the Cre recombinase from this vector, a terminator sequence may be included upstream of the recombination site of the first vector used in the method of the present invention. This terminator sequence should prevent any undesirable expression of the Cre recombinase following the recombination event. This terminator sequence is preferably different to the terminator sequence, if present, on the original second phage vector. The terminator sequence may, for example, be the λ terminator.
Alternatively, in order to avoid exposure of the recombinant phage vector to Cre recombinase which may be expressed from this second recombinant vector, the recombinant phage particles may be isolated from the host organism.
In a further preferred embodiment of the invention, either the first or second vector further includes
(a) a sequence encoding a detectable label;
(b) an inducible stop codon; and (c) a sequence encoding an enzymatic cleavage site such that the sequences described in (a) to (c) are included in the recombinant phage vector. Preferably, the detectable label is the c-myc peptide label, the inducible stop codon is the amber codon and the enzymatic cleavage site is the subtilisin cleavage site. It will be appreciated that the detectable label allows immunological detection of expressed antibodies without the need to use antibodies against the specific binding pair member. The inducible stop codon allows expression of the polypeptide chains as either a displayed fragment or as a soluble product by using either suppressor or nonsupressor strains oi E.coli for expression. The enzymatic cleavage site facilitates release of the phage from the specific binding pair member.
In a further preferred embodiment, the first vector is pUX-1 and the second phage vector is pMOX-1.
In a second aspect the present invention consists in a phage vector which includes a nucleic acid sequence encoding a promoter sequence, a first recombination site downstream and adjacent to the promoter sequence and an open reading frame for Cre recombinase positioned downstream and adjacent to the recombination site such that the promoter drives expression of the Cre recombinase.
In a preferred embodiment of the second aspect of the present invention, the promoter sequence is derived from a promoter for a gene encoding a selectable marker. Preferably, the selectable marker is a gene encoding resistance to an antimicrobial agent. More preferably, the antimicrobial agent is chloramphenicol.
In a further preferred embodiment of the second aspect of the present invention the recombination site is the loxP sequence. Preferably, the vector further includes a second recombination site which is different to the first recombination site. The second recombination site is preferably a mutant of the loxP sequence, more preferably the 7αxP511 sequence.
It will be understood that the method of the present invention may be used to produce phage display vectors which are suitable for preparing combinatorial libraries of antibodies. The specific binding pair member may therefore be an antibody or an antibody fragment. The first polypeptide chain may, for example, be an immunoglobulin heavy chain and the second polypeptide chain may be an immunoglobulin light chain, or vice versa. The phage vector used in the method of the present invention is designed to transiently express the Cre recombinase until exchange between the two vectors occurs. In particular, the promoter is used to drive Cre recombinase gene expression until recombination occurs. The recombination event substantially silences expression of the Cre recombinase and therefore gives rise to a stable recombinant phage vector. In a preferred form of the invention the recombination event results in an exchange of genetic material between the first and second vectors such that the Cre recombinase open reading frame is transferred from the second phage vector to the first vector.
In a preferred form of the invention, the recombinant phage vector not only includes sequences encoding two separate polypeptide chains of a specific binding pair member, but also includes a functional selectable marker. This provides a means for selecting microorganisms containing recombinant phage vectors.
In order that the present invention may be more clearly understood, a preferred form thereof will be described with reference to the following examples and figures in which:
Figure 1. Diagnositic RE analysis of MC05. Lanes 1 to 4 are undigested MC05 clones 1 and 2, MCOl and MC03 respectively. Lanes 5 to 8 are Sad digested MC05 clones 1 and 2, MCOl and MC03 respectively and indicates that MCOδ remains undigested whereas MCOl and MC03 are linearised. Lanes 10 to 13 are Xbal digested MC05 clones 1 and 2, MCOl and MC03 respectively and indicates that MC05 remains undigested whereas MCOl and MC03 are linearised. Lanes 14 to 17 are EcoRI digested MC05 clones 1 and 2, MCOl and MCO3 respectively and indicates that all plasmids are linearised with this RE. Lane 9 is lambda DNA digested with Hindlll and EcoRI as molecular weight markers.
Figure 2. PCR amplification of the LacVH cassette from MCO5. Lanes 2 to 5 are the PCR products of MC05 (lanes 2 and 3) and MC03 (lane 4) and the no template control (lane 5) using MC19 and MC28 as primers. MC05 produces a product of approximately 950bp and MCO3 produces a product of 2.5kb as expected. Lane 1 is lambda DNA digested with HindDI and EcoRI as molecular weight markers.
Figure 3. Diagnostic RE analysis of pBIISK-Pcat. Lanes 1 to 9 are mini prep clones 3, 4, 6 to 12 of pBLISK-Pcat digested with Bglll and Sail. C is pBπSK(BglII) digested with Bgiπ and Sail. The banding pattern indicates that all clones except clone 11 has the 250bp Peat fragment cloned into pBHSK(Bgiπ). M is lambda DNA digested with HindHI and EcoRI as molecular weight markers. Ms is pBluescript plasmid DNA digested with Haem as molecular weight markers.
Figure 4. PCR amplification of the Cre recombinase gene. Lanes 1 and 2 is the PCR products of p35Scre using primers MC25 and MC26. p35Scre produces a PCR product of ~lkb as expected. M is lambda DNA digested with Hindiπ and EcoRI as molecular weight markers.
Figure 5. Diagnostic RE analysis of clones of pBHSKcre. C is the control DNA [pBπS (Bgiπ)] digested with BssHII and Xbal. Lanes 3, 4, 5, and 7 are the respective clones of pBIISKcre digested with BssHII and Xbal as indicated. An Xbal digest was expected to linearise the control and clones.
The expected fragment sizes for the pBssHH RE digest were 2.8kb, 861bp and
352bp for the clones and 2.9kb and 51bp for the control DNA. The banding pattern indicates that the Cre PCR product has been cloned into pBIISK(BglH). M is lambda DNA digested with HindHI and EcoRI as molecular weight markers.
Figure 6. Diagnostic RE analysis of clones of pBHSKterm. The reaction products of clones 1 to 5 are shown on the left panel and clones 6 to 10 in the right panel. Three diagnostic reactions were performed for each clone: a) digested with Sail and Xbal (left lane); b) PstI (middle lane); and c) undigested (right lane). The Xbal and Sail double digest releases the 380bp Term fragment as indicated. M is lambda DNA digested with Hindlll and EcoRI as molecular weight markers. (Note that undigest DNA for clones 5 and 10 are not shown).
Figure 7. Diagnostic RE analysis of clones of pBHSK-TLVH. The control DNA [pBIISK(Bgiπ) - lanes 1 and 2)] and each clone (1, 3, 6, and 9 - lanes 3 to 8) were digested with Sad (left) and PstI, Sail plus Bglll (right lane). As expected the Sad digest linearises the plasmid and the triple digest releases the 950bp LacVH fragment and the 380bp Term fragment as indicated - these fragments are not present in the control DNA. M is lambda DNA digested with HindHI and EcoRI as molecular weight markers. Ms is pBluescript plasmid DNA digested with HaeDI as molecular weight markers. Figure 8. Diagnostic RE analysis of pMOX. Clones 9 and 11 of pMOX were digested with Xbal and HindHI (lanes 1 and 2 respectively) which releases the 250bp Peat fragment that is the same size as an Xbal and HindHI digest of pBHSKPcat-Cre (lane 3). Similarly, clones 9 and 11 of pMOX were digested with Sail and PstI (lanes 4 and 5 respectively) which releases the 380bp Term fragment that is the same size as a Sail and PstI digest of pBHSK-TLVH (lane 6). M is lambda DNA digested with HindHI and EcoRI as molecular weight markers. Ms is pBluescript plasmid DNA digested with HaeBJ as molecular weight markers.
Figure 9. Diagnostic screening for pUX. Twelve clones were digested with PstI (left lane) and undigested (right lane) to screen for the inclusion of the LacVH fragment cloned into pUTcat. Lane C is similarly digested vector pUTcat. Clone 11 clearly has the lacVH fragment cloned into the PstI site since it is releasing a fragment of ~950bp that is a similar size to the LacVH
PCR product (lane L) and which the control DNA does not have (left lane C). It is also clearly evident that the undigested supercoiled DNA is larger than the control DNA (right lane C). M is lambda DNA digested with HindHI and EcoRI as molecular weight markers.
Figure 10. Analysis of the orientation of the LacVH insert of pUX clone 11. pUX clones 10, 11 and 12 were digested with Ball (lanes 1, 2 and 3 respectively). A 700bp fragment is released for the correct orientation and 1120bp for the incorrect orientation. Lane 2 clearly indicates that the LacVH fragment in clone 11 is in the correct orientation. pUX clones 10, 11 and 12 were also digested with BglH (lanes 5, 6 and 7 respectively) and indicates that pUX is linearised as expected. M is lambda DNA digested with HindHI and EcoRI as molecular weight markers.
Figure 11. Diagnostic RE analysis of pUX-TT. The isolate clone of pUX-TT was digested with Xhol (lane 1), Spel (lane 2), Xhol and Spel (lane 3) and undigested (lane 5). The double digest releases the 600bp TT heavy chain DNA sequence. Lane 4 is Xhol and Spel digested pUX. M is lambda DNA digested with HindHI and EcoRI as molecular weight markers. Figure 12. Diagnostic RE analysis of pMOX-TT. Twelve clones (1 to 12) were digested with Sad and Xbal (left lane) and undigested (right lane) to screen for the inclusion of the TT light chain DNA fragment cloned into pMOX. Lane C is similarly digested vector pMOX. All clones clearly have the TT fragment cloned into the Sad and Xbal sites since a fragment of ~600bp is released which the control DNA does not have (left lane C). It is also clearly evident that the undigested supercoiled DNA for each clone is larger than the control DNA (right lane C). M is lambda DNA digested with HindlH and EcoRI as molecular weight markers.
Figure 13. Diagramatic representations of pMOX (a) and pUX (b).
Figure 14. Diagramatic representation of the proposed mechanism of in vivo recombination between the pMOX and pUX vectors.
Figure 15. Diagramatic representation of the recombinant phage vector pMUX.
EXAMPLES Construction of the Lac VH cassette
The LacVH cassette was based on the antibody expression vector MCOl (Ward et al., 1996), which contains cloning sites for both the heavy and light chain DNA sequences. The first part of the construction of the cassette was to remove the Xbal restriction endonuclease (RE) site (3' cloning site of the light chain) from MCOl. Following digestion with Xbal, MCOl was treated with klenow fragment of DNA polymerase I (blunted) and subsequently religated and transformed into E. coli strain XLl-blue. Twenty transformants were selected and subjected to RE and gel electrophoretic analysis. Fifteen of these clones were found to be devoid of the Xbal site. One construct, designated MCO4, was retained for further work. The second part of the construction was to remove the light chain leader region from EcoRI to Sad sites. MC04 was digested with Sad, gel purified and redigested with EcoRI. The double cut MC04 DNA was then subjected to klenow treatment to 'fill-in' the cohesive ends, ligated and transformed into XLl-blue. This construction procedure destroyed the Sad site but retains the integrity of the EcoRI site. Twenty transformants were randomly selected and subjected to RE analysis with EcoRI, Sad and Xbal. At least 10 clones were isolated that displayed the expected profile. This construct is referred to as MC05.
In order to positively determine whether these recombinants were devoid of the 86bp light chain leader sequence, the nucleotide sequence of this region was determined for four clones using MC03.for (MC28) PCR primer. All four clones were found to be devoid of the said sequence and one clone was retained. Figure 1 indicates that MC05 but not MCOl and MC03 (which has stuffer fragments cloned into the light and heavy chain cloning sites) are linearized by Sad and Xbal, while all three MCO vectors are linearized with EcoRI. As expected, it is also evident that MC05 is slightly smaller than MCOl.
A 956bp fragment corresponding to position 90 and 987 of MC05 was then amplified by the polymerase chain reaction (PCR) using primers MC19 and MC28. The resultant PCR product, designated as the LacVH cassette, contained starting from the 5' end, a unique PstI site, the lacZ promoter and operator sequence (lacZ P/O), the pel B leader sequence, Xhol and Spel unique RE sites, a myc tag, an amber point mutation, a subtilisin open reading frame (ORF), the gene HI ORF, a translational stop codon, a mutated loxP site (designated loxPδll) and a unique BglH site [Figure 2].
The loxPδll site was introduced into the cassette with the reverse primer MC19, which incorporated a loxPδll DNA sequence. Intramolecular excision events have been noted where recombination occurs between two loxP sites that are in the same orientation of the DNA substrate (Abremski et al., 1986). In order to avoid this problem in the final construct (pMOX), and in the recombinatorial vector, the loxPδll sequence was positioned in the opposite orientation with repect to the wild type loxP site.
The amplified LacVH cassette was subsequently used in the construction of both the acceptor phage vector and the donor plasmid vector.
Construction of pMOX
This vector was based on MCOl and was designed to transiently express 'cre' recombinase until an exchange between vectors has occured. The chloramphenicol acteyltransferase (CAT) gene promoter (Peat) is used to drive the cre-recombinase gene expression. Between the Peat promoter and the Cre gene is the loxP sequence which is one of two designated recombination sites.
Construction of pMOX involved the PCR amplification of four discrete fragments that were cloned into MCOl. These fragments are referred to as: Peat, which contains the chloramphenicol promoter and the loxP site 3' of the promoter; Cre, which contains the sequences necessary to express the creatin recombinase protein; Term, which contains ribonuclease terminator sequences; and LacVH, which contains the cloning site for the heavy chain of an antibody and the loxPδll site 3' of the gene HI stop codon.
Construction of the Pcat-Cre cassette
The Peat element was successfully amplified from the CAT gene residing on the plasmid pACYCl84 using the primers MC27 and MC17. To determine the efficacy of the amplified Peat element and whether the loxP site interfered with transcription, the PCR product was cloned into the promoter-probed vector pkk232-8. Following blunting with Klenow to remove the terminal A's, the Peat PCR product was digested with HindHI and cloned into the HindHI/Smal site of pkk232-8. The ligation mix was used to transformed XLl-blue cells and promoter efficiency determined by spreading the cells on LB agar plates containing varying (10-50mg) concentrations of chloramphenicol. Five Peat clones were isolated and were subjected to PCR and gel electrophoretic analysis. All five were found to harbour the Peat element (including the loxP site) indicating that the Peat promoter was not compromised because of the presence of the loxP site. Attempts to clone the Peat element into the vector pBltSK(BglH)
[kindly provided by Dr. Guy Lyons, Kanamatsu Laboratory, University of Sydney] using the unique Xbal and HindHI RE sites were unsuccessful. To facilitate cloning of the Peat element, two further primers were designed (MC50 and MC51) that amplified the Peat PCR product and also contained additional HindHI RE sites at both ends of the PCR product. The Peat PCR fragment and pBltSK(BglH) were digested with HindHI RE, purified in an agarose gel, ligated, and used to transform XLl-blue cells. Twelve transformants were selected and subjected to RE and gel electrophoretic analysis. Eight clones were found to contain the Peat PCR fragment and one clone was selected for further work and named pBltSK-Pcat. Figure 3 indicates that the Peat fragment is released by HindHI RE digestion of this plasmid.
The cre recombinase ORF (including the ribosome binding site RBS) was amplified from pBS157 [kindly provided by Dr Peter Waterhouse, CSIRO Division of Plant Industry, Canberra, Australia] with primers that were designed using the E. coli Pl nucleotide sequence derived by Sternberg et al. (1986). These two primers (MC25 and MC26) incorporated unique HindlH and Sail RE sites. After successful amplification of the Cre fragment (Figure 4) the product was digested with HindlH and Sail, and ligated into HindlH and Sail digested pBltSK(BglH). The ligation mix was used to transform XLl- blue cells and eleven of 12 single colonies screened by RE analysis were shown to contain the Cre gene. Four clones further characterised by RE analysis showed the expected banding patterns (Figure 5). Clone 3 was designated pBltSK-Cre and used for further manipulations. The Pcat-Cre cassette was constructed by cloning the Peat fragment
(from pBltSK-Pcat) into pBltSK-Cre. This was performed by digesting both pBltSK-Pcat and pBltSK-Cre with Xbal and HindHI. The 4kb fragment from pBltSK-Cre and the 250bp fragment from pBltSK-Pcat were agarose gel purified and ligated. The ligation products were used to transform XLl-blue cells and 12 single colonies were isolated. Initial screening indicated that 10 of the 12 clones had the Peat fragment cloned into the pBltSK-Cre vector. Further diagnostic digests were performed on the clones and one was designated pBltSK-PcatCre and used in subsequent manipulation.
Construction of Term-Lac VH cassette
In order to prevent read through and interference from Peat, the E. Coli. 5s ribosomal transcription terminator (rrnbTlT2) [Brosius et al., 1981] was positioned adjacent to the 3' end of the Cre ORF. The rrnbTlT2 terminator was successfully amplified from pkk232-8 using the primers MC24 and MC23, generating a product of 340bp. The transcriptional terminator product was restricted with Sail and PstI and ligated into the cloning vector pSP72. The fragment was subsequently extracted from this vector by digestion with Sail and PstI, and ligated into PstI and Sail digested pBltSK(BglH). The ligation mix was used to transform XLl-blue cells and 12 single colonies were isolated and screened for the inclusion of the Term fragment. All 12 colonies contained the Term fragment (figure 6) and one was selected, further characterized and designated pBltSK-Term. This plasmid was used for subsequent manipulations.
The next stage in acceptor phage vector construction was to clone the LacVH gene into pBltSK-Term, to produce the Term-Lac VH cassette. As described above a 956bp fragment had been PCR amplified from MCOδ. New primers (MC48 and MC49) were designed to extend the ends of that fragment, adding HindHI cloning sites to both ends. A fragment of appropriate size was amplifiable using these two primers and the original PCR product as template. The PCR product and pBltSK-Term were then digested with PstI and BglH, gel purified and ligated. The ligation reaction was used to transform XLl-blue cells and 12 single colonies were isolated and screened for the inclusion of the LacVH fragment. Eleven of the 12 colonies contained the LacVH gene. Further RE diagnostic digests were performed (Figure 7) and one clone was selected and designated pBltSK-TLVH. This clone was used for subsequent DNA manipulations.
Construction of pMOX
The final step in the construction of pMOX involved digesting: a) MCOl with Xbal and BglH; b) pBltSK-TLVH with BglH and Sail; and c) pBltSK-PcatCre with Sail and Xbal. The MCOl vector, TLVH and PcatCre cassettes were purified in an agarose gel, mixed and ligated. The ligation mix was used to transform XLl-Blue cells and 12 colonies were isolated and screened for the correct construction. Figure 8 indicates expected restriction digest patterns of the resultant pMOX vector.
Construction of pUX
Construction of pUX was based on pUCl9 (Yanisch et al., 1985). Since both the donor and acceptor vectors possessed the same antibiotic resistance (ampicillin - ApR) determinant, the ApR gene of pUC19 was replaced with a PCR amplified Tetracyclin resistance (TcR). The entire TcR gene was amplified from pACYCl84, using primers that included Pvul RE sites at both ends of the PCR product (MC21 and MC22). The TcR gene was restricted with Pvul, and ligated with the 1790bp Pvul restricted fragment of pUCl9. This fragment was partially devoid of the ApR coding region (thereby making it sensitive to Ap), as well as the coding region for lacZ. The ligation mixture was then transformed into the Tc E. coli sensitive strain NM522, and recombinants were selected for resistance to Tc. Following Pvul RE analysis one clone (designated pUT-1, 3209bp) was retained.
The remainder of the vector was constructed by cloning two PCR generated fragments into the MCS of pUC19. These fragments are referred to as: CAT (which contains the sequences that induce resistance to chloramphenicol); and LacVH (which contains the cloning site for the heavy chain of an antibody).
The chloramphenicol resistance gene (the ORF excluding its promoter region) was PCR amplified using primers MC18 and MC20. The cat gene primers were based on the nucleotide sequence of the cat gene of the plasmid Tn9 (Alton and Vapnek, 1979). After amplifcation the loxP-cat gene was restriced with SacI/PstI and ligated into Sacl/Pstl restricted pUT-1 vector. The ligation mixture was transformed into NM522 and mini-plasmid lysate preps of eighteen randomly chosen isolates were analysed by RE and gel electrophoresis. Additional characterization of four clones with PCR revealed that all four clones (designated pUTcat) contained, the loxP-cat gene.
The next step in the construction of pUX was to clone the lacVH gene into the PstI site. This was accomplished by amplifying the LacVH PCR fragment described earlier with primers (MC48 and MC58) that added a PstI site to both ends of the LacVH gene. The PCR fragment and pUTcat was restricted with PstI, the DNA was purified in an agarose gel and the DNA ligated. The ligation mixture was transformed into NM522 cells and mini- plasmid lysate preps of eighteen randomly isolated clones were analysed by RE and gel electrophoresis. One clone contained the DNA insert (Figure 9) which, with additional RE analysis, was shown to be in the correct orientation (Figure 10). This clone was designated pUX.
In vivo recombination of pUX and pMOX To test for 'in vivo' recombination between pUX and pMOX, the heavy chain of a tetanus toxoid (TT) Fab was cloned into pUX, while the light chain was cloned into pMOX. Phage was then prepared from pMOX- TT, and was used to infect log phase HB2151 cells previously transfected with pUX-TT.
Construction of pUX-TT and pMOX-TT The tetanus toxoid heavy chain was RE digested with Xhol/Spel and purified in an agarose gel from MCOl-TT. This fragment was ligated into Xhol/Spel RE digested pUX. The ligation mixture was used to transform HB2151 cells and a single colony was isolated. This colony was screened using RE digests and gel electrophoresis for the inclusion of the TT heavy chain DNA. Figure 11 indicates that this clone contained the TT heavy chain DNA sequences. The tetanus toxoid light chain was RE digested with Sacl Xbal and purified in an agarose gel from MCOl-TT. This fragment was ligated into Sacl/Xbal RE digested pMOX. The ligation mixture was used to transform XLl-blue cells and 12 colonies were isolated and screened using RE digests and gel electrophoresis for the inclusion of the TT light chain. Figure 12 indicates that all 12 colonies contained the TT light chain DNA sequences. These two plasmids were referred to as pUX-TT and pMOX-TT.
Preparation of pMOX-TT phase. pMOX-TT was transformed into XLl-blue and 250μl of an overnight culture was used to inoculate 2YT containing 2% glucose, carbenicillin (carb - 50μg/ml)tetracycline (tet - lOμg/ml) and then rescue with helper phage (VCS- M13). The culture was incubated for 2 hours at 37°C with shaking and thencentrifuged at room temperature at 4500rpm for 15 minutes. The bacterial pellet was resuspended in 50ml of 2YT containing carb 50μg/ml, tetlOμg/ml and kanamycin 70μg/ml and incubated overnight at 37°C with shaking. The bacteria were pelleted by centrifugation at δOOOrpm at room temperature. The phage were precipitated from the supernatant by adding l/5vol 20% PEG6000/2.5M NaCl, mixing and leaving on ice with occasional shaking for 1 hour. The phage were collected by centrifugation at δOOOrpm for 20 minutes at 4°C. The pellet was resuspended in 500μl of 1% BSA, and bacterial debris was removed by a high speed centrifugation in a microfuge tube and stored at 4°C.
In vivo recombination between pUX-TT and pMOX-TT
A 1ml culture of pUX transformed HB2151 cells in media containing tetracycline (OD600 = 0.8) were infected with 1x109 pMOX-TT phage and allowed to stand at 37°C for 30 minutes. Carb (25μg/ml) was added and the culture incubated for 30 minutes with shaking. Further carb (25 μg/ml) was added and incubated with shaking for a further 3 hours. An aliquot of cells added and incubated with shaking for a further 3 hours. An aliquot of cells (250μl) was obtained 1 and 4 hours after infection and plated onto: a) Carb; b) Tet; c) ChlorlO; d) ChlorδO; e) Carb/ChlorlO; and f) Carb/Chlor50.
Since pMOX is tet sensitive and pUX is carb sensitive, growth of cells in culture indicated that the cells contain both pMOX and pUX.
Chloramphenicol further selects for cells that have recombinants containing the pMUX vector since chloramphenicol resistance is acquired only after recombination. A lawn of colonies were observed on both chlor and carb/chlor plates (at both concentrations of chlor) following infection of pMOX-TT into the culture containing HB2151/pUX-TT indicating that recombination had occurred.
It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.
List of Primers MC03.for (MC28) 5 '..ACC TGC AGA ACA GTG AGC GCA ACG CAA T..3' PstI site for cloning MCθ3.rev (MC19) 5'..GAA GAT CTT CFAT AAC TTC GTA TAT ACA TAT GTA TAC GAA GTT AT1G CGG CCG CTT AAA TTA ATT AGC..3' Bglll site for cloning and [ioxPδll] recombination site Pca for (MC50) 5'CCC AAG CTT GGG CTC TAG AGC CGA CGC ACT TTG
CGC CGA AT..3' Forward primer for Peat PCR fragment; Xbal and Hindlll PcatPCR.rev (MC51) 5'..CCC AAG CTTCCCAAG CTTGGG ATA ACT TCG
TAT AGC ATA CAT TAT..3' Reverse primer for Peat PCR fragment with LoxP site; Hindlll.
Pcatfor (MC27) 5'..GCT CTA GAG CCG ACG CAG TTT GCG CCG ATT..3'
Reverse primer for the amplification of LacVH of pMOX. Pcatrev (MC17) 5'..GGG AAG CTT CCC fATA ACT TCG TAT AGC ATA CAT TAT ACG AAG TTA T1TC GAT AAC TCA AAA AAT ACG CC..3' Reverse PCR primer for amplification of the CAT gene promoter fro Tn9. Hindlll for cloning and UoxPλ Cre.rev (MC25) 5'..ACG CGT CGA CCG CGT TAA TGG CTA ATC GC..3'
Reverse primer for the amplification of cre recombinase of pMOX. Cre.for (MC26) 5'..CCC AAG CTT CTG AGT GTT AAA TGT CCA ATT TAC.3' Forward primer for the amplification of cre recombinase of pMOX. Term.for (MC24) 5'..ACG CGT CGA CCA GAA GTG AAA CGC CGT A..5'
Forward primer for the amplification of terminator for pMOX. Term.rev (MC23) 5 '..TTC TGC AGT TCC TGA TGA TGC AAA AAC GAG
GC..3' Reverse primer for the amplification of terminator of pMOX. MCO5.for (MC48) 5'..CCC AAG CTT GGG ACC TGC AGA ACA GTG AGC
GCA ACG CAA T..3' Forward primer for PCR of LacVH of pMOX;
Psu, Hindlll MCOδ.rev (MC49) 5'..CCC AAG CTT GGG AAG ATC TTC ATA ACT TCG
TAT ATA CAT A..3' Reverse primer for PCR of LacVH with loxP site; Bglll, Hindlll. tetrev (MC21) 5'..TAC GAT CGT ATT CAC AGT TCT CCG CAA GA..3'
Reverse primer for the amplification of tetR for pUX. tetfor (MC22) 5'..ATC GAT CGA TCA AAT GTA GCA CCT GAA GTC AG..3'
Forward primer for the amplification of tetR for pUX. catfor (MC18) 5'..CGA GCT CGfA TAA CTT CGT ATA ATG TAT GCT ATA
CGA AGT TAT1 GAT TTT CCA GGA GCT AAG GAA..3' Forward
PCR primer for the amplification of the CAT resistance gene from
Tn9; Sad, UoxP] eatrev (MC20) 5'..TTT GCA GAT CGT CAA TTA CCT CCA CG..3' Reverse primer for amplification of CatR gene for pUX.
MCO.rev PPCR (MC58) 5'..AAA ACT GCA GCC AAG ATC TTC ATA ACT
TCG TAT ATA CAT A..3' Reverse PCR primer for LacVH MCO PCR product; PstI, Bglll
Abremski, K., Frommer, B. and Hoess, R. H. (1986) Linking-number changes in the DNA substrate during Cre-mediated loxP site-specific recombination. Journal of Molecular Biology 192(l):17-26.
Alton, N. K. and Vapnek, D. (1979) Nucleotide sequence analysis of the chloramphenicol resistance transposon Tn9. Nature 282(5741) :864-9.
Brosius, J., Dull, T. J., Sleeter, D. D. and Noller, H. F. (1981) Gene organization and primary structure of a ribosomal RNA operon from Escherichia coli. Journal of Molecular Biology 148(2) :107-27.
Sternberg, N., Sauer, B., Hoess, R. and Abremski, K. (1986) Bacteriophage
Pl cre gene and its regulatory region. Evidence for multiple promoters and for regulation by DNA methylation. Journal of Molecular Biology 187(2) :197-212.
Ward, R. L., Clark, M. A., Lees, J., Hawkins, N. J. (1996) Retrieval of human antibodies from phage-display libraries using enzymatic clevage. J. Immunol. Methods. 189: 73-82.
Yanisch-Perron, C, Vieira, J. and Messing, J. (1985) Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mpl8 and pUCl9 vectors. Gene 33(1):103-19.
|1||*||CURRENT BIOLOGY, 4, 12, ZOU et al., "Cre-loxP-Mediated Gene Relacement: A Mouse Strain Producing Humanized Antibodies", pp 1099-1103, 1994.|
|2||*||FEBS LETTERS, 377, DAVIES & REICHMANN, "An Antibody VH Domain With a lox-Cre Site Integrated Into Its Coding Region: Bacterial Recombination Within a Single Polypeptide Chain", pp 92-96, 1995.|
|3||*||GENE, 176, TSURUSHITA et al., "Phage Display Vectors for In Vivo Recombination of Immunoglobulin Heavy and Light Chain Genes to Make Large Combinatorial Libraries", pp 59-63, 1996,|
|4||*||NUCLEIC ACIDS RESEARCH, 21, 9, WATERHOUSE et al., "Combinatorial Infection and In Vivo Recombination: a Strategy for Making Large Phage Antibody Repertoires", pp 2265-2266, 1993.|
|Brevetto con rif.||Data di registrazione||Data di pubblicazione||Candidato||Titolo|
|WO1999025821A1 *||17 nov 1998||27 mag 1999||Pioneer Hi Bred Int||Compositions and methods for genetic modification of plants|
|WO2004001036A1 *||18 giu 2003||31 dic 2003||Univ California||Compositions and methods for selecting open reading frames|
|EP1574573A2 *||17 nov 1998||14 set 2005||Pioneer Hi-Bred International, Inc.||Compositions and methods for genetic modification of plants|
|EP2189539A1||10 nov 2009||26 mag 2010||Chimera Biotec GmbH||Conjugate complexes for analyte detection|
|US6143557 *||20 gen 1999||7 nov 2000||Life Technologies, Inc.||Recombination cloning using engineered recombination sites|
|US6171861||12 gen 1998||9 gen 2001||Life Technologies, Inc.||Recombinational cloning using engineered recombination sites|
|US6187994||17 nov 1998||13 feb 2001||Pioneer Hi-Bred International, Inc.||Compositions and methods for genetic modification of plants|
|US6262341||17 nov 1998||17 lug 2001||Pioneer Hi-Bred International, Inc.||Method for the integration of foreign DNA into eukaryotic genomes|
|US6270969||20 gen 1999||7 ago 2001||Invitrogen Corporation||Recombinational cloning using engineered recombination sites|
|US6277608||22 apr 1999||21 ago 2001||Invitrogen Corporation||Recombinational cloning using nucleic acids having recombination sites|
|US6300545||17 nov 1998||9 ott 2001||Pioneer Hi-Bred International, Inc.||Mobilization of viral genomes from T-DNA using site-specific recombination systems|
|US6331661||17 nov 1998||18 dic 2001||Pioneer Hi-Bred International, Inc.||Method for directional stable transformation of eukaryotic cells|
|US6410329||18 mag 2000||25 giu 2002||Novartis Finance Corporation||Method for achieving site specific integration of exogenous DNA delivered by non-biological means to plant cells|
|US6455315||12 nov 1999||24 set 2002||Pioneer Hi-Bred International, Inc.||Compositions and methods to stack multiple nucleotide sequences of interest in the genome of a plant|
|US6458594||12 nov 1999||1 ott 2002||Pioneer Hi-Bred International, Inc.||Compositions and methods for the targeted removal of a nucleotide sequence from the genome of a plant|
|US6541231||12 ott 1999||1 apr 2003||Pioneer Hi-Bred International, Inc.||Method for the integration of foreign DNA into eukaryotic genomes|
|US6552248||12 nov 1999||22 apr 2003||Pioneer Hi-Bred International, Inc.||Compositions and methods for locating preferred integration sites within a plant genome|
|US6573425||12 nov 1999||3 giu 2003||Pioneer Hi-Bred International, Inc.||Compositions and methods to reduce the complexity of transgene integration in the genome of a plant|
|US6624297||6 dic 1999||23 set 2003||Pioneer Hi-Bred International, Inc.||Compositions for the genetic modification of plants|
|US6664108||1 ott 1999||16 dic 2003||Pioneer Hi-Bred International, Inc.||Mobilization of viral genomes from T-DNA using site-specific recombination systems|
|US6720140||4 feb 2000||13 apr 2004||Invitrogen Corporation||Recombinational cloning using engineered recombination sites|
|US6828093||24 lug 1998||7 dic 2004||Baylor College Of Medicine||Rapid subcloning using site-specific recombination|
|US7102055||6 dic 1999||5 set 2006||Pioneer Hi-Bred International, Inc.||Compositions and methods for the targeted insertion of a nucleotide sequence of interest into the genome of a plant|
|US7179599||23 mag 2003||20 feb 2007||Pioneer Hi-Bred International, Inc.||Mobilization of viral genomes from T-DNA using site-specific recombination systems|
|US7223601||29 gen 2003||29 mag 2007||Pioneer Hi-Bred International, Inc.||Method for the integration of foreign DNA into eukaryotic genomes|
|US7361508||16 mag 2003||22 apr 2008||Pioneer Hi-Bred International, Inc.||Compositions and methods for the targeted insertion of a nucleotide sequence of interest into the genome of a plant|
|US7364902||7 apr 2006||29 apr 2008||Pioneer Hi-Bred International, Inc,||Mobilization of viral genomes from T-DNA using site-specific recombination systems|
|US7405079||7 mag 2003||29 lug 2008||Pioneer Hi-Bred International, Inc.||Compositions and methods to reduce the complexity of transgene integration into the genome of a plant|
|US7462766||4 mag 2006||9 dic 2008||Pioneer Hi-Bred International, Inc.||Compositions comprising non-identical recombination sites|
|US7560622||1 ott 2001||14 lug 2009||Pioneer Hi-Bred International, Inc.||Methods and compositions relating to the generation of partially transgenic organisms|
|US7572634||7 mag 2003||11 ago 2009||Pioneer Hi-Bred International, Inc.||Compositions and methods for locating preferred integration sites within the genome of a plant|
|US7807868||2 apr 2008||5 ott 2010||Pioneer Hi-Bred International, Inc.||Mobilization of viral genomes from T-DNA using site-specific recombination systems|
|US7820880||6 nov 2008||26 ott 2010||Pioneer Hi-Bred Int'l. Inc.||Compositions and methods to stack multiple nucleotide sequences of interest in the genome of a plant|
|US8143504||22 ott 2010||27 mar 2012||Pioneer Hi-Bred International, Inc.||Compositions and methods for genetic modification of plants|
|US8536420||1 ago 2008||17 set 2013||Pioneer Hi-Bred International, Inc.||Compositions and methods for genetic modification of plants|
|US8685893||28 lug 2008||1 apr 2014||Genentech, Inc.||Phage display|
|US8735158||28 feb 2008||27 mag 2014||Pioneer Hi-Bred International, Inc.||Compositions and methods for the targeted insertion of a nucleotide sequence of interest into the genome of a plant|
|US8883988||28 giu 2012||11 nov 2014||Life Technologies Corporation||Compositions for use in recombinational cloning of nucleic acids|
|US8927210||20 nov 2009||6 gen 2015||Chimera Biotec Gmbh||Conjugate complexes for analyte detection|
|US8945884||13 mag 2013||3 feb 2015||Life Technologies Corporation||Methods and compositions for synthesis of nucleic acid molecules using multiplerecognition sites|
|US9222098||12 ago 2003||29 dic 2015||Christopher L. Baszczynski||Compositions for the targeted insertion of a nucleotide sequence of interest into the genome of a plant|
|Classificazione internazionale||C12N15/10, C12N15/13, C12N15/62, C07K16/00, C40B40/02, C12N15/09|
|Classificazione cooperativa||C07K2319/00, C07K16/00, C12N15/62, C40B40/02, C07K2319/735, C12N15/1037|
|Classificazione Europea||C12N15/10C1, C07K16/00, C40B40/02, C12N15/62|
|13 mar 1997||AL||Designated countries for regional patents|
Kind code of ref document: A1
Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM
|13 mar 1997||AK||Designated states|
Kind code of ref document: A1
Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM
|24 apr 1997||DFPE||Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)|
|2 lug 1997||121||Ep: the epo has been informed by wipo that ep was designated in this application|
|3 mar 1998||ENP||Entry into the national phase in:|
Ref country code: CA
Ref document number: 2231045
Kind code of ref document: A
Format of ref document f/p: F
Ref document number: 2231045
Country of ref document: CA
|2 apr 1998||WWE||Wipo information: entry into national phase|
Ref document number: 1996928283
Country of ref document: EP
|1 lug 1998||WWP||Wipo information: published in national office|
Ref document number: 1996928283
Country of ref document: EP
|2 lug 1998||REG||Reference to national code|
Ref country code: DE
Ref legal event code: 8642
|23 gen 2001||WWW||Wipo information: withdrawn in national office|
Ref document number: 1996928283
Country of ref document: EP